Skip to content. | Skip to navigation

Personal tools

Donald Yapp

Peer-Reviewed Papers



Yapp DT, Wong MQ, Kyle AH, Valdez SM, Tso J, Yung A, Kozlowski P, Owen DA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Ng SS. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis. 19: 229-244. (2016).

Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB, Yapp DT. Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. Scientific reports. 6: 18537. (2016).

Mu C, Chang SW, Prosser KE, Leung AW, Santacruz S, Jang T, Thompson JR, Yapp DT, Warren JJ, Bally MB, Beischlag TV, Walsby CJ. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization, Inorg Chem. 55(1):177-90. (2016).



Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB. Determination of an optimal dosing schedule for combining Irinophore C and temozolomide in an orthotopic model of glioblastoma. Journal of controlled release : official journal of the Controlled Release Society. 220, 348-357. (2015).

Ramogida CF, Pan J, Ferreira CL, Patrick BO, Rebullar K, Yapp DT, Lin KS, Adam MJ, Orvig C. Nitroimidazole-Containing H2dedpa and H2CHXdedpa Derivatives as Potential PET Imaging Agents of Hypoxia with (68)Ga, Inorg Chem. 54: 4953-4965. (2015).

Pasiliao CC, Chang CW, Sutherland BW, Valdez SM, Schaeffer D, Yapp DT, Ng SS. The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC cancer. 15: 266. (2015).

Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT. Irinophore C, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. Journal of controlled release : official journal of the Controlled Release Society. 199: 72-83. (2015).



Yang H, Miao Q, Johnson BF, Rishel MJ, Sossi V, Dinelle K, Benard F, Yapp DT, Webster JM, Schaffer P. A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the x(C)(-) transporter. Bioorganic & medicinal chemistry letters. 24(23): 5512-5515. (2014). 

Webster JM, Morton CA, Johnson BF, Yang H, Rishel MJ, Lee BD, Miao Q, Pabba C, Yapp DT, Schaffer P. Functional imaging of oxidative stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid. Journal of nuclear medicine. 55(4): 657-664. (2014). 

Liu Z, Radtke MA, Wong MQ, Lin KS, Yapp DT, Perrin DM. Dual mode fluorescent (18)F-PET tracers: efficient modular synthesis of rhodamine-[cRGD]2-[(18)F]-organotrifluoroborate, rapid, and high yielding one-step (18)F-labeling at high specific activity, and correlated in vivo PET imaging and ex vivo fluorescence. Bioconjugate chemistry. 25(11): 1951-1962. (2014). 

Liu Z, Pourghiasian M, Radtke MA, Lau J, Pan J, Dias GM, Yapp D, Lin KS, Benard F, Perrin DM. An organotrifluoroborate for broadly applicable one-step 18F-labeling. Angew Chem Int Ed Engl. 53(44): 11876-11880. (2014) 

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 20: 3159-3173. (2014).



Yapp DT, Ferreira CL, Gill RK, Boros E, Wong MQ, Mandel D, Jurek P, Kiefer GE. Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA, Mol Imaging 12, 263-272. (2013). 

Webb MI, Wu B, Jang T, Chard RA, Wong EW, Wong MQ, Yapp DT, Walsby CJ. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions. Chemistry. 19(50): 17031-17042. (2013). 

Liu Z, Li Y, Lozada J, Wong MQ, Greene J, Lin KS, Yapp D, Perrin DM. Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging, Nuclear medicine and biology. 40(6): 841-849. (2013). 

Li Y, Liu Z, Lozada J, Wong MQ, Lin KS, Yapp D, Perrin DM. Single step 18F-labeling of dimeric cycloRGD for functional PET imaging of tumors in mice. Nuclear medicine and biology. 40(8): 959-966. (2013).

Huang R, Langille G, Gill RK, Li CM, Mikata Y, Wong MQ, Yapp DT, Storr T. Synthesis, characterization, and biological studies of emissive rhenium-glutamine conjugates, Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry. 18(7): 831-844. (2013).



Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB. Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. Journal of controlled release : official journal of the Controlled Release Society. 158: 34-43. (2012).

Ferreira CL, Yapp DT, Mandel D, Gill RK, Boros E, Wong MQ, Jurek P, Kiefer GE. (68)Ga small peptide imaging: comparison of NOTA and PCTA. Bioconjugate chemistry. 23: 2239-2246. (2012).

Boros, E, Ferreira CL, Yapp DT, Gill RK, Price EW, Adam MJ, Orvig C. RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga, Nuclear medicine and biology. 39: 785-794. (2012).



Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (Lond). 2011 Nov;6(9):1645-54. (2011).

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R)) or vincristine. BMC Cancer. 11:124. (2011).



Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. J Pharm Sci. 99(6):2839-53. (2010).


Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB, Yapp DT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res. 14(22):7260-7l. (2008).

Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther. 7(1):59-70. (2008).

Ferreira CL, Yapp DT, Lamsa E, Gleave M, Bensimon C, Jurek P and Kiefer GE. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals Nucl Med Biol. 35(8):875-82 (2008).

Hoff MN, Yapp DT, Yung AC, Oliver TS, Kozlowski P. In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy Int J Radiat Biol. 84(3):237-42 (2008).


Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. (2007).

Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int. 99(5):1154-60. (2007).


Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2(11):606-19. (2004).

Skov K, Adomat H, Bowden M, Dragowska W, Gleave M, Koch CJ, Woo J, Yapp DT. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res. 162(5):547-53. (2004).


Yapp DT, Yap SY. Lansium domesticum: skin and leaf extracts of this fruit tree interrupt the lifecycle of Plasmodium falciparum, and are active towards a chloroquine-resistant strain of the parasite (T9) in vitro. J Ethnopharmacol. 85(1):145-50. (2003).


Yapp DT,Steed J, Yap SY and Houghton P.J.. The isolation and structural characterization of n-Methyl-4-hydroxyproline from the fruit skin of Lansium spp. Cryst. Acta E. Vol. E58, p. 988-989 (2002).


Doiron A, Yapp DT, Olivares M, Zhu JX, Lehnert S. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Cancer Res. 59(15):3677-81. (1999).

Yapp DT, Lloyd DK, Zhu J, Lehnert S. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device. Radiother Oncol. 53(1):77-84. (1999).


Clas SD, Yapp DT and Zhu XX. Polymeric materials for pharmaceutical applications: Processing and testing. Recent Res. Devel. in Macromol. Res.3, p. 475 - 503 (1998).

Yapp DT, Lloyd DK, Zhu J, Lehnert SM. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int J Radiat Oncol Biol Phys. 42(2):413-20. (1998).

Yapp DT, Lloyd DK, Zhu J, Lehnert SM. Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice. Anticancer Drugs. 9(9):791-6. (1998).


Yapp DT, Lloyd DK, Zhu J, Lehnert SM. Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation. Int J Radiat Oncol Biol Phys. 39(2):497-504. (1997).

Yapp DT, Rettig SJ, James BR and Skov KA. Bidentate sulfoxide complexes of ruthenium(II) and their preliminary biological assessment in vitro Inorg. Chem. Vol. 36, p. 5635 - 5641 (1997).


Jaswal J, Yapp DT, Rettig SJ, James BR and Skov KA. Routes to ruthenium(II)bromo(sulfoxide) complexes, including the synthesis and structural characterization of a neutral dilithium/diruthenium(II) complex containing terminal and bridging tetramethylenesulfoxide ligandsInorg. Chim. Acta. Vol. 207, p. 97 - 103 (1993).



Jaswal J, Yapp DT, Rettig SJ, James BR and Skov KA. A diruthenium(II)-dilithium complex containing four different bonding types of tetramethylenesulfoxide ligands J. Chem. Soc. Chem. Comm. p. 1528 - 1530 (1992).


Yapp DT, Jaswal J, Rettig SJ, James BR and Skov KA.  Synthesis and structural characterization of cis-dichlorotetrakis (tetramethylenesulfoxide-S) ruthenium(II) and mertrichlorotris(tetrahydrothiophene) ruthenium(III). Inorg. Chim. Acta. 177, p. 199 - 204 (1990).




Back to Donald Yapp 

Back to Main Page